Home Stelis Biopharma And Pieris Forge Alliance For Novel Anticalin Therapeutics In Ophthalmology
 

Keywords :   


Stelis Biopharma And Pieris Forge Alliance For Novel Anticalin Therapeutics In Ophthalmology

2013-12-30 06:46:05| drugdiscoveryonline News Articles

Stelis Biopharma (formerly Agila Biotech), a subsidiary of Strides Arcolab Limited, focused on biotherapeutic drug development and bio-manufacturing, and Pieris AG, a next generation therapeutic protein R&D company, recently announced the initiation of a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology

Tags: in alliance forge ophthalmology

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11How Japan's youngest CEO transformed Hello Kitty
31.10Unicharm to Expand in Africa
31.10Essity Named Diversity Leader by Financial Times
31.10Maxcess to Make FIFE Guiding Products in Mumbai
More »